Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in Children and Adolescents With Type 2 Diabetes
NCT03170518Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Canagliflozin with Placebo (2 arms). Primary endpoints: Change From Baseline in Glycated Hemoglobin (HbA1c) at 26 weeks and Percentage of Participants With Treatment-emergent Adverse Events at 56 weeks. Started Jul 2017; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03170518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170518.